Navigation Links
Proactive monitoring of inflammatory bowel disease therapy could prolong effectiveness
Date:9/11/2014

BOSTON Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient's chances of having a long-term successful response to therapy, a pilot observational study at Beth Israel Deaconess Medical Center concludes.

The study, published in the Inflammatory Bowel Diseases, evaluated the levels of infliximab, an antibody designed to bind to and block the effects of TNF-alpha, an inflammatory protein found in high levels in patients with IBD, such as Crohn's disease and ulcerative colitis, and numerous other inflammatory conditions such as rheumatoid arthritis and psoriasis. More commonly known as Remicade, infliximab is one of four anti-TNF agents used to treat these inflammatory diseases when they do not respond to or are intolerant of conventional therapies.

Infliximab has a good record of inducing and maintaining remission of IBD in patients with moderate to severe disease. But the therapy has not proven durable in treatment, primarily, researchers believe, because of the body's formation of antibodies to the medication. Only two-thirds of patients initially respond to infliximab and at one year less than half of the patients remain in remission. Additionally, it is estimated that 10 percent of patients on infliximab will lose response to the drug each year. This is significant because it is often prescribed with the expectation that patients will remain on it indefinitely.

Proactive therapeutic monitoring of a drug is common in other clinical scenarios, including solid organ transplant. In 2009, with that standard in mind, BIDMC attending physician Adam S. Cheifetz, MD began monitoring infliximab levels in his IBD patients with the goal of gradually adjusting their dosing regimens to hopefully improve long-term efficacy and decrease toxicity.

The pilot observational study of 48 patients found proactive monitoring of infliximab concentrations resulted in a significantly better chance of continuing on therapy than in patients who received the standard treatment and dosing regimen. The main reasons for this seemed to be less disease recurrence and fewer infusion reactions in the group that underwent proactive trough concentration monitoring. The authors hypothesize that maintaining a target infliximab concentration prevents the formation of antibodies to the therapy, which are implicated in loss of response to the drug and infusion reactions.

"Currently physicians are not routinely checking infliximab levels," said Cheifetz, Director of Center for Inflammatory Bowel Disease at BIDMC and an Associate Professor of Medicine at Harvard Medical School. "In our study, patients who did not have proactive monitoring were three times more likely to stop infliximab. Therefore, we are proposing that all patients have routine monitoring of IFX concentrations and adjustment of dose based on the level, even if clinically well."

Cheifetz noted "this would be a huge paradigm shift for patients on IFX. Instead of just weight based dosing with empiric dose escalation for symptoms, we propose monitoring the serum drug concentrations and adjusting the dose to achieve a drug concentration within the therapeutic range."

The next step, he said, is verifying this with prospective studies as well as creating a pathway or algorithm for a provider to follow when prescribing IFX. This novel approach may have ramifications for other inflammatory diseases including rheumatoid arthritis and psoriasis, as well as for other biologic therapies (such as Humira) used to treat these conditions.


'/>"/>

Contact: Jerry Berger
jberger@bidmc.harvard.edu
617-667-7308
Beth Israel Deaconess Medical Center
@BIDMChealth
Source:Eurekalert

Related medicine news :

1. SingleSource Background Screening Company Calls On Adults To Take Proactive Approach To Stop Child Sexual Abuse
2. Diabetes Support Supplements, a Product from ProactiveLife Celebrates First Year Launch
3. ProActive Chiropractic Volunteering at the Susan G. Komen Breast Cancer Walk
4. Dr. Andrew Cohen of ProActive Chiropractic Recaps the 2013 Chiropractic Sports Sciences Symposium
5. High Bit Security: 2/3 of All Data Breaches Preventable With Proactive Security Testing, New Ponemon Institute Study Documents Breach Causes and Costs
6. Triple Anti-Oxidant Liver Formula, a Proactive Approach to Dealing with Environmental Toxins, is Now Available for a Complimentary Trial
7. ZeptoMetrix Corporation (ZMC) in Collaboration with CytoSignet, Inc. to Offer Proactive, Patented* and Extensive Bed Bug Detection Products
8. Proactive Use of Florastor Probiotics Make for Happy, Healthy Holidays
9. Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility
10. Proactive office ergonomics can increase job satisfaction and employee retention
11. Role of Screening, Monitoring in Early Kidney Disease Unclear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... ... Keflezighi and the American Heart Association (AHA)-San Diego Chapter to raise awareness of ... Stroke Walk on Saturday, September 21 in Balboa Park alongside National University System ...
(Date:9/17/2019)... ... 2019 , ... Drs. Charles Felts and Elizabeth Felts Randall ... TN for customized full mouth dental implants with TeethXpress® . TeethXpress treatment ... a permanent tooth replacement solution for patients who struggle with the pain and ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Japan . ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... on the detection and treatment of infectious diseases at its annual Congress ... were noninvasive detection of residual HIV infected cell persistence and the development ...
(Date:9/11/2019)... ... ... A September 2 article on CBS News details a new ... to suffer heart attacks, strokes, kidney failure, and heart disease versus a control group ... specialists Dr. Feiz and Associates says the study adds further evidence to an overwhelming ...
Breaking Medicine News(10 mins):
(Date:9/18/2019)... (PRWEB) , ... September 18, ... ... parent organization to ReachMD, Global Learning Collaborative, and other healthcare-focused subsidiaries, today ... environment, DecisionSimâ„¢, uses real-world cases to challenge healthcare professionals (HCPs) to make ...
(Date:9/18/2019)... ... 2019 , ... The interns of NJ Lenders Corp. recently spent their time ... Foundation (YCS) in Hackensack , where NJ Lenders donated $1,000 worth of school supplies ... them a pizza party and handed out ice cream. , NJ Lenders is a ...
(Date:9/18/2019)... ... ... U.S. Dermatology Partners was a proud sponsor of the 9th Annual ... took place at Lake Ray Hubbard in Rockwall. Over 340 swimmers raised $270,000 and ... helps fund phase 1 clinical trials for cancer research for difficult to treat cancers ...
Breaking Medicine Technology: